Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
How do you utilize (1,3)-beta-D-glucan in CSF for diagnosing and monitoring non-cryptococcal CNS fungal infections?
Related Questions
Do you treat with antibiotics active against methicillin-resistant staphylococci when a patient's culture grows non-lugdunensis, coagulase-negative staphylococci that tests susceptible to oxacillin by phenotypic testing, given the low constitutive PbP2A production of most CoNS?
What clinical criteria do you use to decide whether to continue intravenous gentamicin or fluoroquinolone for the full duration of treatment or to step down to oral therapy in hospitalized patients with tularemia?
Would you treat Scedosporium growth in expectorated sputum in a patient with COPD, pulmonary hypertension, and bronchiectasis, who has chronic dyspnea with exertion, thick sputum production, negative bacterial cultures, and no signs of mold infection on a high resolution CT scan, with no other clinical symptoms of infection?
Would you still treat with course for osteomyelitis if proximal bone cultures after amputation are still positive but pathology does not demonstrate osteomyelitis?
What is your approach to antibiotic prophylaxis for spontaneous bacterial peritonitis in patients with cirrhosis?
Do you routinely test for co-infection of other tick-borne illnesses in a patient who tests positive for Lyme, anaplasmosis, babesiosis, or ehrlichiosis?
Do you prefer a specific clinical scoring system to determine if a patient needs to be tested for Group A Streptococcal pharyngitis?
When would you consider long-term suppressive antibiotic therapy in patients with chronic or recurrent bacterial prostatitis who continue to experience symptoms despite multiple courses of antibiotics?
Do you routinely recommend transition to dual PO antibiotic coverage for strep species and MRSA, for patients with purulent cellulitis and in the absence of culture data?
Would you give long term antistreptococcal antibiotic prophylaxis to a patient who presents with features of poststreptococcal reactive arthritis but who also meets criteria for Acute Rheumatic Fever?
